Logistics

1. FONT II STUDY Logistics • 6 Month treatment period • Visits at weeks 0, 2, 8, 16 and 26 • 5 year follow up period • 1 year clinic visits • 4 year telephone contact • Central laboratory: All tests provided • Central pharmacy: Aptuit • Paper reports faxed to Core for data entry

2. FONT II STUDY Inclusion criteria • Primary FSGS confirmed by renal biopsy • Failure to respond to prior therapy at least one of the following immunosuppressive medications-cyclosporine, tacrolimus, MMF, sirolomus • Age 1-50 years at onset of proteinuria • Estimated GFR ≥40 ml/min/1.73 m2 at screening and ≥30 ml/min/1.73 m2 at randomization

3. FONT II STUDY Inclusion criteria • Up/c > 1.0 g/g creatinine on first morning void • Steroid resistance defined as failure to achieve sustained Up/c <1.0 following a standard course of prednisone/prednisolone/methylprednisolone OR contraindication/anticipated intolerance to steroid therapy.

4. FONT II STUDY Exclusion criteria • Organ transplantation • Congestive heart failure • History of prior myocardial infarction • SLE or multiple sclerosis • Hepatic disease defined as serum AST/ALT >2.5X upper limit of normal • Hematocrit <27% • Immunosuppressive therapy with cyclosporine, Tacrolimus, MMF, azathioprine, rapamycin, or cyclophosphamide in the 30 days prior or Rituximab in the 90 days prior to randomization • Prior treatment with adalimumab or rosiglitazone • Allergy to study medications • Abnormal pap smear (more than CIN I)

5. FONT II STUDY Exclusion criteria • Lactation, pregnancy, or refusal of birth control in women of child‑bearing potential • Participation in another therapeutic trial involving protocol mandated administration of a immunosuppressive medication concurrently or 30 days prior to randomization • Active/serious infection (including, but not limited to hepatitis B or C, HIV) • History of malignancy • Abnormality in age appropriate cancer screening in accord with ACS 2003 guidelines • Uncontrolled BP > 140/95 or > 95th percentile for age/height at the end of the run in period • Diabetes mellitus Type I or II.

6. FONT II STUDY Screening visit • History and Physical exam • HIV, HEP B/C if not done in the past 12 mos • PPD if not done in the past 12 months • All labs to Spectra, with 2 specimens for Up/c • Existing renal biopsy tissue sent to study pathologist to confirm FSGS

7. FONT II STUDY Screening visit-key points • Review all CRFs for completion/accuracy • Ensure that the patient has a negative cancer screening according to the ACS 2003 guidelines • Patients should be on target doses of lisinopril and losartan by the end of the screening period (prior to week 0 visit) • Schedule week 0 visit once you have received drug from Aptuit

8. FONT II STUDY Cancer Screening Overview • Age > 21 and female: Annual Pap smear. • Age > 40 and female: Annual Pap smear AND mammogram. • Age > 50: Annual screen for occult fecal blood. • Age > 50 and male: Annual screen for occult fecal blood and PSA Cancer screening is essential because of the use of adalimumab

9. B01 to B02 Timeline • Baseline (01) screening and Baseline (02) visit must be completed >2 weeks but <12 weeks. • This ensures: • ACEi/ARB treatment was implemented for a minimum of 2 weeks prior to randomization • The initiation of novel therapy does not coincide with the start of the ACEi/ARB combination treatment. This is a safety feature to avoid randomizing participants who have a hemodynamically induced decline in GFRe below 30 ml/min/1.73 m2.

10. FONT II STUDY Medications Adalimumab (Humira) • SQ injection every other week • Dose is 24 mg/m2/dose • Maximum dose 40 mg

11. Rosiglitazone (Avandia) Oral tablets administered bid Dose is 4 mg/m2/day (max 8 mg) Dose modified based on Phase I PK study FONT II STUDY Medications

12. FONT II STUDY Medications

13. FONT II STUDY Randomization • Fax all forms to your core site for data entry • Once your patient is randomized you will receive -initial prescription report -drug allocation report • Drug will be shipped to your site from Aptuit within 1-2 business days

14. FONT II STUDY Drug Distribution Center(APTUIT) • Drugs provided: Atorvastatin Avandia, Humira • Prescription for: lisinopril and losartan • Drugs will be shipped from Aptuit once patient is randomized

15. FONT II STUDY Central Laboratory (Spectra East) • CBL measurements: Urine protein/creatinine, urine pregnancy testing, all serum chemistries, fasting lipid profile, hematology, Screening for HIV, HEP B, and HEP C • Spectra to send kits with Fed Ex labels, shipping boxes, tubes, collection cups, ice packs, etc. • Spectra faxes routine results to PSs, transmits results to central data base overnight. • Immediate “panic reports” of life-threatening values

16. FONT II STUDY Visits • All Forms are available on line • Visits should be held within 3 days on either side of target date • Once week 0 visit is entered, a visit schedule will be sent to site

17. Schedule of Visits and Procedures

18. FONT II STUDY Adverse EventSerious Adverse Event • Use AE and SAE Forms • Complete promptly • Report to local IRB as needed • Follow up as soon as AE/SAE resolves

19. FONT II STUDY Reimbursement • $1200 per center start-up • Effort for IRB application and contract • Pharmacy start-up • Administrative fees • Dispersed upon receipt of IRB approval and signed contract with Clinical Coordinating Center • $3375 per patient enrolled

20. DCC Reports Eligibility (every other day until participant is randomized or considered ineligible) Core Lab (results of urine and or blood/serum samples sent to Spectra) Biopsy Results (sent when Core Pathologist completes/enters F287) AE/SAE (F260, F261 entered; this report will go to NIH Project Officer as well) Reminders (an e-mail stating next visit window and what is expected for that visit) Action Items (BP out-of-range, high or low lab values, etc) DCC e-mail alias is font_dcc@bio.ri.ccf.org